专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明授权

US08280643B2 Crystal structure of Staphylococcus aureus clumping factor A in complex with fibrinogen derived peptide and uses thereof 有权
标题翻译：金黄色葡萄球菌凝集因子A与纤维蛋白原衍生肽复合的晶体结构及其用途
公开(公告)号：US08280643B2
公开(公告)日：2012-10-02
申请号：US12459327
申请日：2009-06-30
申请人： Magnus Hook , Ya-Ping Ko , Emanuel Smeds , Vannakambadi K. Ganesh
发明人： Magnus Hook , Ya-Ping Ko , Emanuel Smeds , Vannakambadi K. Ganesh
IPC分类号： G06F19/00 , G01N31/00
CPC分类号： C07K14/75 , A61K38/00 , A61K38/363 , C07K14/31 , C07K16/1271 , C07K16/18 , C07K16/36 , G01N33/68 , G01N2333/31 , G01N2333/75
摘要： The present invention provides a method for determining the structure of a microbial surface components recognizing adhesive matrix molecule in complex with fibrinogen, by providing a ClfA complexed with a fibrinogen gamma-peptide; determining a ClfA binding region of the fibrinogen gamma-peptide; determining one or more critical amino acid residues in the ClfA binding region of a native fibrinogen gamma-peptide that is critical for a ClfA:fibrinogen gamma-peptide interaction; determining one or more amino acid residues of the ClfA that binds to the ClfA binding region of the native fibrinogen gamma-peptide; modeling the structure of the ClfA binding region; determining the structure of the ClfA in complex with the :fibrinogen gamma-peptide interaction; and identifying one or more potential agent(s) that inhibit the ClfA:fibrinogen gamma-peptide interaction without affecting binding of other proteins to the fibrinogen gamma-peptide.
摘要翻译：本发明提供了一种通过提供与纤维蛋白原γ肽复合的ClfA来确定识别与纤维蛋白原复合的粘合剂基质分子的微生物表面成分的结构的方法; 测定纤维蛋白原γ肽的ClfA结合区域; 确定对ClfA：纤维蛋白原γ-肽相互作用至关重要的天然纤维蛋白原γ-肽的ClfA结合区域中的一个或多个关键氨基酸残基; 确定与天然纤维蛋白原γ肽的ClfA结合区结合的ClfA的一个或多个氨基酸残基; 建模ClfA结合区域的结构; 确定与纤维蛋白原γ-肽相互作用复合的ClfA的结构; 以及鉴定抑制ClfA：纤维蛋白原γ-肽相互作用的一种或多种潜在药剂，而不影响其它蛋白质与纤维蛋白原γ-肽的结合。

42. 发明申请

US20100183623A1 MONOCLONAL ANTIBODIES RECOGNIZING A COAGULASE-NEGATIVE STAPHYLOCOCCAL PROTEIN 有权
标题翻译：识别凝集素阴性血清白蛋白的单克隆抗体
公开(公告)号：US20100183623A1
公开(公告)日：2010-07-22
申请号：US11917435
申请日：2006-06-16
申请人： Joseph M. Patti , Jeff T. Hutchins , Andrea Hall , Linda Santos , Maria Bowden , Magnus Hook
发明人： Joseph M. Patti , Jeff T. Hutchins , Andrea Hall , Linda Santos , Maria Bowden , Magnus Hook
IPC分类号： A61K39/40 , C07K16/12 , G01N33/569 , A61P31/04
CPC分类号： C07K16/1271 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/92
摘要： Monoclonal antibodies which can bind to the SdrF protein of Staphylococcus epidermidis are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus epidermidis. The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of the S. epidermidis SdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.
摘要翻译：提供可以结合表皮葡萄球菌的SdrF蛋白的单克隆抗体，其可用于治疗和保护葡萄球菌如表皮葡萄球菌感染。本发明的单克隆抗体是有利的，除了蛋白质本身之外，它们还可以识别表皮葡萄球菌SdrF蛋白的结合结构域和亚结构域。还提供了基于本发明的单克隆抗体的合适的组合物和被动疫苗以及它们的使用方法。

43. 发明授权

US07666438B1 Multicomponent vaccines 有权
标题翻译：多组分疫苗
公开(公告)号：US07666438B1
公开(公告)日：2010-02-23
申请号：US10795267
申请日：2004-03-09
申请人： Joseph M. Patti , Timothy J. Foster , Magnus Hook
发明人： Joseph M. Patti , Timothy J. Foster , Magnus Hook
IPC分类号： A61K39/085
CPC分类号： C07K16/1271 , A61K39/085
摘要： Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of Staphylococcus and other bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes a fibrinogen binding domain of a fibrinogen binding protein and a bacterial component such as ca capsular polysaccharide, and both active and passive vaccines based on these components are also provided, along with methods of treating infection using these compositions and vaccines.
摘要翻译：提供了有助于预防和治疗葡萄球菌感染的多组分疫苗，其包括某些所选择的细菌结合蛋白或其片段的组合，或对那些蛋白质或片段的抗体。通过仔细选择蛋白质，片段或抗体，提供疫苗，其对广泛的葡萄球菌和其他细菌菌株和针对在对数生长曲线的不同阶段表达的蛋白质提供保护。在本发明的一个实施方案中，提供了包含纤维蛋白原结合蛋白的纤维蛋白原结合结构域和诸如ca荚膜多糖的细菌组分的组合物，并且还提供了基于这些组分的主动和被动疫苗以及两者的方法使用这些组合物和疫苗治疗感染。

44. 发明授权

US07153515B2 Method of preventing T cell-mediated responses by the use of the major histocompatibility complex class II analog protein (map protein) from Staphylococcus aureus 有权
公开(公告)号：US07153515B2
公开(公告)日：2006-12-26
申请号：US10041775
申请日：2002-01-10
申请人： Eric Brown , Lawrence Lee , Magnus Hook
发明人： Eric Brown , Lawrence Lee , Magnus Hook
IPC分类号： A61K39/085 , A61K39/02 , A61K45/00 , A61K38/00
CPC分类号： C07K14/31 , A61K38/00
摘要： A method of immunomodulating the T cell response in Staphylococcal bacteria is provided wherein an effective amount of the Map protein from Staphylococcus aureus is administered to a host to prevent or suppress the T cell response. The present method may be utilized with either the Map protein or an effective subdomain or fragment thereof such as the Map 10 or Map 19 protein. The present invention is advantageous in that suppression or prevention of the T cell response in a host can prevent or ameliorate a wide variety of the pathogenic conditions such as T cell lymphoproliferative disease and toxic shock syndrome wherein the overstimulation of T cells needs to be suppressed or modulated.

45. 发明申请

US20060258570A1 Decorin proteoglycan inhibitor of fibrinogen blood clotting 审中-公开
标题翻译： Decorin蛋白聚糖抑制剂的纤维蛋白原血液凝固
公开(公告)号：US20060258570A1
公开(公告)日：2006-11-16
申请号：US11492159
申请日：2006-07-24
申请人： Magnus Hook , Tracey Dugan
发明人： Magnus Hook , Tracey Dugan
IPC分类号： A61K38/36
CPC分类号： C07K14/4725 , A61K38/1709 , A61K47/61 , A61K2300/00
摘要： The present invention provides compositions and methods of inhibiting fibrin(ogen) clot formation by utilizing decorin proteoglycan as an anticoagulating and antithrombotic agent. The decorin proteoglycan comprises a decorin core protein or a fragment thereof covalently linked to a galactosaminoglycan polysaccharide. The decorin core protein acts as an anticoagulant and as a carrier for the delivery of an antithrombotic galactosaminoglycan to fibrinogen. Fibrin clotting is inhibited by the decorin proteoglycan in a concentration-dependent fashion.
摘要翻译：本发明提供了通过利用核心蛋白聚糖蛋白聚糖作为抗凝血和抗血栓形成剂来抑制纤维蛋白（ogen）凝块形成的组合物和方法。核心蛋白聚糖蛋白聚糖包含与半乳糖聚糖多糖共价连接的核心蛋白聚糖蛋白核心蛋白或其片段。核心蛋白聚糖核心蛋白质作为抗凝血剂和作为将抗血栓形成半乳糖聚糖交付给纤维蛋白原的载体。纤维蛋白凝块以浓度依赖性方式被核心蛋白聚糖蛋白聚糖抑制。

46. 发明授权

US06703025B1 Multicomponent vaccines 有权
标题翻译：多组分疫苗
公开(公告)号：US06703025B1
公开(公告)日：2004-03-09
申请号：US09386959
申请日：1999-08-31
申请人： Joseph M. Patti , Timothy J. Foster , Magnus Hook
发明人： Joseph M. Patti , Timothy J. Foster , Magnus Hook
IPC分类号： A61K39085
CPC分类号： C07K16/1271 , A61K39/085
摘要： Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of Staphylococcus bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes at least a collagen binding protein or peptide (or an appropriate site directed mutated sequence thereof) such as CNA, or a protein or fragment with sufficiently high homology thereto, in combination with a fibrinogen binding protein, preferably Clumping factor A (“ClfA”) or Clumping factor B (“ClfB”), or a useful fragment thereof or a protein or fragment with sufficiently high homology thereto. The vaccines and products of the present invention are advantageous in that they respond to the urgent need of the medical community for a substitute for small molecule antibiotics, which are rapidly losing effectiveness and provide effective combinations of the large number of known bacterial surface adhesins which can impart effective protection against a broad spectrum of bacterial infections.
摘要翻译：提供了有助于预防和治疗葡萄球菌感染的多组分疫苗，其包括某些所选择的细菌结合蛋白或其片段的组合，或对那些蛋白质或片段的抗体。通过仔细选择蛋白质，片段或抗体，提供疫苗，其对广泛的葡萄球菌细菌菌株和针对在对数生长曲线的不同阶段表达的蛋白质提供保护。在本发明的一个实施方案中，提供了一种组合物，其包含至少一种胶原结合蛋白或肽（或其适当的定点突变的序列），例如CNA或与其具有足够高同源性的蛋白质或片段，与纤维蛋白原结合蛋白，优选结合因子A（“ClfA”）或凝集因子B（“ClfB”）或其有用片段或与其同源性具有足够高同源性的蛋白质或片段。本发明的疫苗和产品是有利的，因为它们响应医学界迫切需要替代小分子抗生素，其正在快速丧失有效性并提供大量已知细菌表面粘附素的有效组合，其可以有效保护免受广泛的细菌感染。

47. 发明授权

US5980908A Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment 失效
标题翻译：具有纤连蛋白，纤维蛋白原，胶原和层粘连蛋白结合能力的细菌细胞表面蛋白，用于制造蛋白质和预防性治疗的方法
公开(公告)号：US5980908A
公开(公告)日：1999-11-09
申请号：US118697
申请日：1993-09-10
申请人： Magnus Hook , Kjell Martin Lindberg , Torkel Mikael Wadstrom
发明人： Magnus Hook , Kjell Martin Lindberg , Torkel Mikael Wadstrom
IPC分类号： A61K39/085 , A61P31/04
CPC分类号： A61K39/085 , Y10S424/823
摘要： The invention is concerned with a vaccine composition comprising an effective amount of an isolated protein derived from Staphylococcal aureus having the ability to bind fibronectin. The protein has a molecular weight of 165,000 daltons and optionally also contains a protein having a molecular weight of 87,000 daltons. The protein has the ability to elicit antibody production and a level of protein to elicit antibody production. The level of protein is sufficient to produce protection upon challenge with a Staphylococcus aureus bacterial strain in a mammal, particularly a ruminant, by forming antibodies against the Staphylococcus aureus bacterial strain.
摘要翻译：本发明涉及包含有效量的具有结合纤连蛋白能力的金黄色葡萄球菌的分离蛋白质的疫苗组合物。蛋白质的分子量为165,000道尔顿，并且任选地还含有分子量为87,000道尔顿的蛋白质。该蛋白质具有引发抗体产生和蛋白质水平以引发抗体产生的能力。通过形成针对金黄色葡萄球菌细菌菌株的抗体，蛋白质水平足以在用金黄色葡萄球菌细菌菌株在哺乳动物，特别是反刍动物中产生保护。

48. 发明授权

US5770702A Fibronectin binding protein as well as its preparation 失效
公开(公告)号：US5770702A
公开(公告)日：1998-06-23
申请号：US729767
申请日：1996-10-07
申请人： Magnus Hook , Martin Kjell Lindberg , Lars Christer Signas , Torkel Mikael Wadstrom , Gunnar Froman
发明人： Magnus Hook , Martin Kjell Lindberg , Lars Christer Signas , Torkel Mikael Wadstrom , Gunnar Froman
IPC分类号： C07K14/31 , C07K13/00 , C12P21/00
CPC分类号： C07K14/31
摘要： The present invention relates to a new recombinant hybrid-DNA-molecule comprising a nucleotide sequence from S. aureus coding for a protein, or polypeptide, having fibronectin binding properties.

49. 发明授权

US5189015A Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability 失效
标题翻译：通过纤连蛋白和纤维蛋白原结合能力的细菌细胞表面蛋白质对金黄色葡萄球菌细菌菌株的定植进行预防性治疗的方法
公开(公告)号：US5189015A
公开(公告)日：1993-02-23
申请号：US801593
申请日：1991-12-05
申请人： Magnus Hook , Kjell M. Lindberg , Torkel M. Wadstrom
发明人： Magnus Hook , Kjell M. Lindberg , Torkel M. Wadstrom
IPC分类号： C07K14/31
CPC分类号： C07K14/31 , Y10S435/825 , Y10S435/849 , Y10S435/882 , Y10S435/883 , Y10S435/884 , Y10S435/885
摘要： A method for prophylactic treatments of the colonization of a Staphylococcus aureus bacterial strain having the ability to bind to fibronectin in a mammal. The method comprises administering a prophylactic therapeutically active amount of a protein having fibronectin binding properties to a mammal in need of such treatment. The generation of infections, such as mastitis, caused by a Staphylococcus aureus bacterial strain are thereby prevented. The administration may be via vaccination to induce immunization.
摘要翻译：一种用于预防性治疗在哺乳动物中具有结合纤连蛋白的能力的金黄色葡萄球菌菌株的定植的方法。该方法包括向需要这种治疗的哺乳动物施用预防性治疗活性量的具有纤连蛋白结合特性的蛋白质。由此可以防止由金黄色葡萄球菌菌株引起的感染，如乳腺炎的产生。给药可以通过接种来诱导免疫。

50. 发明授权

US08124107B2 Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use 有权
标题翻译：识别CA-MRSA的高表达推定抗原的抗体及其使用方法
公开(公告)号：US08124107B2
公开(公告)日：2012-02-28
申请号：US12279079
申请日：2007-02-22
申请人： Magnus Hook , Maria Labandeira-Rey , Gabriela M. Bowden
发明人： Magnus Hook , Maria Labandeira-Rey , Gabriela M. Bowden
IPC分类号： A61K39/00 , A61K39/38 , A61K39/02 , A61K39/085 , A61K39/09
CPC分类号： C07K14/31 , A61K39/00
摘要： The present invention provides MSCRAMM® proteins from S. aureus which are putative highly-expressed antigens from methicillin-resistant S. aureus, including communit-associated MRSA (CA-MRSA), and these antigens can thus be utilized in methods of generating antibodies capable of binding these antigens which can be useful in methods of treating or preventing infection from MRSA. The present invention is directed to these proteins, antibodies capable of binding these proteins, methods of generating said antibodies, nucleic acids coding for said proteins, and pharmaceutical compositions or vaccines which include the proteins or antibodies of the present invention in combination with a pharmaceutically acceptable vehicle, carrier or excipient.
摘要翻译：本发明提供来自金黄色葡萄球菌的MSCRAMM蛋白，其是来自耐甲氧西林金黄色葡萄球菌的推定的高度表达的抗原，包括共同相关的MRSA（CA-MRSA），因此这些抗原可用于产生抗体的方法可以用于治疗或预防MRSA感染的方法中的这些抗原。本发明涉及这些蛋白质，能够结合这些蛋白质的抗体，产生所述抗体的方法，编码所述蛋白质的核酸，以及药物组合物或疫苗，其包括本发明的蛋白质或抗体与药学上可接受的组合车辆，载体或赋形剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式